Clinical trial
Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA…
NCT00487916 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00487916 |
|---|---|
| Title | Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum |
| Official title | Phase 1 Study of the Safety, Reactogenicity and Immunogenicity of AMA1-C1/ISA 720: A Blood Stage Vaccine for Plasmodium Falciparum |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Drug |
| Interventions | AMA1-C1/ISA 720 |
| Enrollment | 150 |
| Start date | Jun 13, 2007 |
| Primary completion | Feb 5, 2009 |
| Completion | Feb 5, 2009 |
| First posted | Jun 19, 2007 |
| Last update posted | Jul 2, 2017 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: